Immuneering earnings were -$66.5M for the trailing 12 months ending Sep 30, 2026, with N/A growth year over year. The latest IMRX earnings report on Sep 30, 2026 announced Q3 2026 earnings of -$24.2M, up 40.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, IMRX reported annual earnings of -$56.0M, with -8.2% growth.
On IMRX's earnings call on Oct 29, 2026, Immuneering (NASDAQ: IMRX) reported Q3 2026 earnings per share (EPS) of -$0.37, up 2.63% year over year. Total IMRX earnings for the quarter were -$24.19 million. In the same quarter last year, Immuneering's earnings per share (EPS) was -$0.38.
As of the last Immuneering earnings report, Immuneering is currently losing money. Immuneering's net profit (also called net income) for the twelve months ending Sep 30, 2026 was -$66.50 million, a 6.41% increase year over year.
What was IMRX's earnings growth in the past year?
As of Immuneering's earnings date in Oct 29, 2026, Immuneering's earnings has grown year over year. IMRX earnings in the past year totalled -$66.50 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.